Introduction
============

Although immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) significantly extend overall survival (OS) in patients with diverse types of cancer, it could benefit only a limited subpopulation of patients[@B1]. Hence, there is an urgent need to investigate the rational and effective strategies to improve the efficacy of ICIs in patients with cancer. Understanding genomic correlates of response to ICIs could help the development of novel biomarkers and therapies to enhance the clinical response and expand the benefit population[@B2], [@B3].

The AT-rich interaction domain 1A (*ARID1A*) is a subunit of the chromatin remodeling complex SWI/SNF, which facilitates access of proteins to DNA. *ARID1A* is one of the most commonly mutated genes in cancer[@B4], [@B5]. A recent study found that *ARID1A* loss and impaired *ARID1A* binding to the mismatch repair (MMR) protein MSH2 similarly reduced MMR and increased mutation frequency and the number of tumor-infiltrating lymphocytes and PD-L1 expression. In mice with *ARID1A*-deficient ovarian cancer, PD-L1 inhibitor resulted in reduced tumor volume and better survival compared with controls[@B6]. Then, several retrospective and exploratory studies reported the relationship between *ARID1A* alterations and clinical benefit to ICI in some cancers. These findings suggested that *ARID1A* alteration would not only cooperate with ICI treatment but also have the potential predictive value for ICI therapy. However, a comprehensive analysis of *ARID1A* alteration frequency and its predictive value for ICI treatment outcome in diverse cancers has not yet been investigated.

In this study, we performed this pan-cancer analysis by using online database to systematically characterize the prevalence and predictive value of *ARID1A* alterations across multiple cancer types. We found a relatively high frequency (6.2%) of *ARID1A* alterations and significant predictive value for ICIs treatment in \>40,000 patients with cancers. We also investigated the association between *ARID1A* alterations and tumor mutation burden (TMB) level or immune cell infiltrations. The current evidence suggested that *ARID1A* alterations would yield promising predictive value for ICI treatment across diverse cancers.

Results and discussion
======================

Genetic alterations of *ARID1A* and its association with TMB level
------------------------------------------------------------------

In this study, we defined *ARID1A* alterations as all kinds of nonsynonymous mutations including missense, frame-shift, splice site, nonstop, nonsense, fusions, deletions and translation start site changes. The frequency of *ARID1A* alterations in 40167 patients with various cancers was 6.2% (Figure [1](#F1){ref-type="fig"}A), with patients with endometrial cancer having the highest levels of *ARID1A* alterations (37.2%). Most of the alterations were missense mutations (39.6%, 979/2471; Supplemental [Figure S1](#SM0){ref-type="supplementary-material"}). The prevalence and spectrum of *ARID1A* alterations were slightly different in early-stage (TCGA cohort; Supplemental [Figure S1](#SM0){ref-type="supplementary-material"}A) versus advanced-stage cancers (MSK-IMPACT cohort; Supplemental [Figure S1](#SM0){ref-type="supplementary-material"}B). Co-occurring of genetic mutations in cancers with *ARID1A* alterations were not uncommon and some of them are popular driver genes in cancers (e.g. *KMT2D/A/C, PTEN, POLE*, etc.) (Figure [1](#F1){ref-type="fig"}B). Of note, co-occurring landscape of genetic mutations in cancers with *ARID1A* alterations was totally distinct in early-stage (TCGA cohort; Supplemental [Figure S2](#SM0){ref-type="supplementary-material"}A) versus advanced-stage cancers (MSK-IMPACT cohort; Supplemental [Figure S2](#SM0){ref-type="supplementary-material"}B). Considering *ARID1A* alterations promoting cancer mutability[@B6], [@B7], we then investigate the difference of TMB level between *ARID1A* alteration and wild type groups. We selected a subset generated from MSK-IMPACT cohort that ensure the TMB could be comparable[@B8]. In the MSK-IMPACT cohort[@B8], 10945 samples were identified and 912 (8.3%) of them had*ARID1A* alterations. TMB of patients with *ARID1A* alterations was significantly higher than it in those without (9 vs. 4 mutations/Mb,*P* \< 0.0001; Figure [1](#F1){ref-type="fig"}C). This was validated in two ICI-treated cohorts (*P* \< 0.0001, *P* = 0.0012, respectively; Figure [1](#F1){ref-type="fig"}C and D)[@B3], [@B9]. Notably, cancers with multiple *ARID1A* alterations had the highest TMB level (Supplemental [Figure S2](#SM0){ref-type="supplementary-material"}C-E). These results were consistent with a recent study, which also reported that the mutation load was significantly elevated in *ARID1A*-mutant tumors[@B6]. Together, these findings reveal a high prevalence of *ARID1A* alterations and its close relationship with TMB level across cancer types, suggesting that *ARID1A* alterations could be considered as biomarkers when conducting ICI treatment.

Predictive and prognostic value of *ARID1A* alterations
-------------------------------------------------------

Next, we evaluated the association between *ARID1A* alterations and clinical outcome in both whole group and ICI-treated cohort. We firstly found that patients with *ARID1A* alterations showed a significantly longer disease-free survival or progression-free survival \[DFS/PFS, not reached vs 142 months, hazard ratio (HR) = 0.74, 95% confidence interval (CI) 0.64-0.91, *P* = 0.0026; Figure [2](#F2){ref-type="fig"}A\] but markedly shorter OS (68 vs 109 months, HR = 1.30, 95% CI 1.22-1.47, *P* \< 0.0001; Figure [2](#F2){ref-type="fig"}B) than those without in whole group. In early-stage cancers, *ARID1A* alterations were also correlated with longer DFS/PFS (*P* = 0.0005; Supplemental [Figure S3](#SM0){ref-type="supplementary-material"}A). However, the prognostic value of *ARID1A* alterations was only found in advanced-stage cancers (*P* = 0.0094; Supplemental [Figure S3](#SM0){ref-type="supplementary-material"}C) instead of early-stage cancers (*P* = 0.2086; Supplemental [Figure S3](#SM0){ref-type="supplementary-material"}B). In the ICI treatment cohort[@B9], we firstly identified 1661 patients with different cancers receiving ICI therapy and 193 of them with *ARID1A* alterations (Supplemental [Table S1](#SM0){ref-type="supplementary-material"}). Interestingly, patients with *ARID1A* alterations had a substantially prolonged OS of 28 months vs 18 months in the wild-type group (HR = 0.73, 95% CI 0.61-0.93, *P* = 0.0092; Figure [2](#F2){ref-type="fig"}C). Subgroup analysis revealed that patients with multiple *ARID1A* alterations had the longest OS than those with single *ARID1A* alterations or without (not reached vs. 27 vs. 18 months, *P* = 0.0225; Figure [2](#F2){ref-type="fig"}D). Of note, we did not observe the association between*ARID1A* alterations and OS in patients with microsatellite-stable (MSS) solid tumors (*P* = 0.4075; Supplemental [Figure S4](#SM0){ref-type="supplementary-material"}A). Even in patients with multiple *ARID1A* alterations and MSS solid tumors, we also did not found the close association (*P* = 0.4899; Supplemental [Figure S4](#SM0){ref-type="supplementary-material"}B). These findings were consistent with previous publications that *ARID1A* alterations contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with ICI treatment[@B6].

Immune landscape of cancer with *ARID1A* alterations
----------------------------------------------------

To unravel the potential mechanism of the predictive value of *ARID1A* alterations for ICI treatment, we then surveyed the relationship between *ARID1A* alterations and six common immune infiltrates (B cells, CD4^+^ T cells, CD8^+^ T cells, macrophages, neutrophils and dendritic cells) across different cancer types[@B10]. Interestingly, *ARID1A* deficiency was correlated with significantly higher six immune infiltrates in most of the cancer types, especially CD8^+^ T cells, including endometrial cancer (Figure [3](#F3){ref-type="fig"}A), stomach carcinoma (Figure [3](#F3){ref-type="fig"}B) and colon adenocarcinoma (Figure [3](#F3){ref-type="fig"}C). However, patients with *ARID1A*-mutant renal clear cell carcinoma had dramatically lower CD8^+^ T cell infiltrations than those without (Figure [3](#F3){ref-type="fig"}D). Of note, copy number variations (either deletion or amplification) of *ARID1A* were associated with substantially lower six immune infiltrates in most of the cancer types including endometrial cancer, gastric cancer, colon adenocarcinoma, head and neck cancer, lung squamous cell carcinoma and breast invasive carcinoma (Supplemental [Figure S5](#SM0){ref-type="supplementary-material"}).

Conclusions
===========

To our knowledge, this study firstly reported a high frequency of *ARID1A* alterations and the predictive significance of *ARID1A* alterations for ICI treatment in multiple cancer types. We also observed that *ARID1A* alterations were associated with significantly higher TMB level. Although *ARID1A* alterations were correlated with significantly inferior OS in total populations, they were associated with significantly prolonged OS in ICI treatment cohort, suggesting it might be used to predict a survival benefit from ICI therapy across multiple cancer types. Notably, patients with*ARID1A* alterations were correlated with markedly high immune infiltrates in endometrial, stomach and colon cancer but dramatically lower CD8^+^ T cell infiltrations in*ARID1A*-mutant renal clear cell carcinoma, indicating the association between *ARID1A* alterations and immune infiltrates was cancer-dependent. Collectively, our findings highlight the important value of*ARID1A* alterations as pan-cancer predictive biomarkers for ICI treatment.
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